🚨 We’re hiring! 🚨 Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info:

Exciting news! Our survey report with @ECDC_EU on #HIV #stigma in the #healthcare setting is now available. Huge thanks to everyone who contributed to its success! 👉 https://t.co/b1gJZ6p1xL Don't miss the presentation on Friday by @TeyNoori at #AIDS2024

Vibeke Klastrup presenting metanalysis of ATI studies showing smaller reservoir size and interventions such as #bNAbs are associated with duration of viral control during treatment interruptions. #AIDS2024

How to interpret and how to manage low level viremia? Hearing now from @JesperGunst with important insight from amazing session chair @Rokx1 at #YINGconf24

Onto my fave topic - analytical treatment interruptions: where ART is stopped in an #HIVcure study. Viral rebound. Tongcui Ma showed T cell features (pic 1) and Mauro Garcia showed IgG antibodies (pic 2) impacted time to viral rebound. Use as biomarkers for TVR? #CROI2024

The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec! Complete it today or spread the word in your network. 🔄 Available in 38+ languages! 🌍 Survey link: https://t.co/FxThqDHwnV @ECDC_EU

Editorial: “Host Receptor Targeting to Treat #Covid19” by @JesperGunst and Ole Schmeltz Søgaard https://t.co/SaOv3GWzau #SARSCov2 #InfectiousDisease @AarhusUni_int @AUHdk @syctong @Josh_S_Davis @jasonroberts_pk

If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by @ECDC_EU and @EACSociety ⏲️ Deadline: 30 November 2023 #StigmaFree

Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. https://t.co/SaOv3GWzau

Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation. 🌟 Fully funded doctoral positions for translational projects 🌟 Open for applications until Nov 22 https://t.co/5trDu8pVoK

@ECDC_EU @ECDC_HIVAIDS @EACSociety

European AIDS Clinical Society (EACS) vil undersøge viden og holdninger om HIV blandt sundhedsfaglige på tværs af Europa. Så hvis du har ca. 10 min til at udfylde - vil vi blive glade! @Sygeplejeraadet @laegeforeningen @Sundpol @regionerne https://t.co/ftw7zJS4tj

In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1

Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection. @viruseradicate https://t.co/e3JH3rm3m7

Results from the Titan Study show promise that broadly neutralising antibodies (BNABS) are a component of a future HIV Cure.

#TITAN #HIV #HIVcure #bNAbs #TLR Funding by @GileadSciences

Lastly, thanks to all our collaborators. My mentor: @ole_s_sogaard @AUHdk @HealthAarhusUni @AarhusUni_int @NussenzweigL @AwesomeJonesLab @AlfredHealth @TheDohertyInst @DAREtoCureHIV @Oslounivsykehus @UniOslo @AalborgUH @OUHhospital @AmagerHvidovre @Rigshospitalet @RHGoedstrup

No added benefit of combining lefitolimod with bNAbs compared to bNAbs alone. The bNAbs are doing something and support further investigation as part of curative strategies. Additionally, we need better assays for bNAb prediction.

No strong evidence of a bNAb-mediated vaccinal effect on HIV-1-specific CD8 T cell response.

During the early phase of ATI, bNAbs prevented HIV reservoir expansion, whereas non-bNAb recipients had expansion of their reservoir.